Therapeutic preparations of FSH, used primarily for treatment of infertility, are calibrated by in vivo bioassay against international standards (IS) derived from different sources deemed appropriate to their use according to pharmacopoeial monographs. Menotrophins, which have been used for several decades to treat infertility, have been calibrated against the IS for urinary FSH and LH (ISU) but are now being replaced by highly purified urinary FSH or rDNA-derived FSH (rFSH).
Introduction
Follicle-stimulating hormone (FSH) is a heterodimeric, heterogeneous glycoprotein hormone which has been identified in most vertebrate species. It has a central role in reproduction and hence is widely used in human (and animal) reproductive medicine both as a therapeutic agent and as a diagnostic analyte. The potency of human urinary gonadotrophins (menotrophins), used for several decades as therapeutic products in reproductive medicine, is defined by their activity in in vivo bioassay expressed as international units (IU) in terms of the international standard (IS) for urinary FSH and luteinising hormone (LH) (ISU) (WHO Expert Committee on Biological Standardization 1964 , 1975 , Storring et al. 1976 . The relative impurity (Giudice et al. 1994) of these materials necessitates the use of bioassays for determining the potency of their dosage forms (Storring 1988) .
Advances in biotechnology have enabled the development of highly purified preparations of urinary-derived and rDNA-derived FSH (rFSH) (De Boer & Mannaerts 1990 , Van Wezenbeek et al. 1990 , Hugues 1994 which have been used successfully in the treatment of infertility (Devroey et al. 1992 , Howles et al. 1994 . However, the origin, purity and structural features (Hard et al. 1990 , Amoresano et al. 1996 , Harris et al. 1996 of rFSH differ from those of naturally derived preparations.
We describe in this paper the results of an international collaborative study carried out by 27 laboratories in 12 countries to compare candidate standards of highly purified human urinary FSH and of rFSH with the ISU.
The aims of the study were to: (1) calibrate urofollitropin in terms of the ISU; (2) assess the need for a standard for rFSH; (3) calibrate rFSH in terms of the ISU; and (4) assess the stability of candidate IS preparations.
Materials and Methods

Materials
Materials distributed for this study are listed in Table 1 and were identified to participants in the study by a letter code only, and except for in vivo bioassays were assumed to have a common nominal potency so that they were all treated as nearly as possible identically. Where assay capacity permitted, two ampoules of the same material but with different codes (coded duplicates) were included to provide an independent assessment of intra-assay variability. For in vivo assays different codes were used, and nominal potencies were given based on the best available information so that in vivo assays using the minimum number of animals were carried out.
Materials evaluated as candidate standards were generously donated by the Ares-Serono Group, Geneva, Switzerland and Organon International B.V., Oss, The Netherlands. The bulk materials arrived at National Institute for Biological Standards and Control (NIBSC) either as an aqueous solution containing 0·83 mg protein per ml (by the Lowry method using human serum albumin as the standard), or as a lyophilised powder containing 27 µg protein (by amino acid analysis) per mg of excipient (1·54% sucrose, 0·46% citrate) which was redissolved in 10 ml water immediately prior to ampouling. These materials were stored at 20 C and +4 C respectively prior to ampouling.
Candidate IS for rFSH and highly purified human urinary FSH These consisted of two batches of ampoules, coded 92/510 and 92/642, containing highly purified human rFSH produced in Chinese hamster ovary (CHO) cells and a batch of ampoules, coded 92/512, containing a preparation of immunoaffinity-purified human urinary FSH. Samples of ampoules of rFSH and highly purified urinary FSH which had been stored at elevated temperatures to provide an assessment of stability were also included in the study. Reports describing the production and characterisation of highly purified FSH Accelerated thermal degradation samples 92/510 stored at +20 C, +37 C, +45 C for 717 or 877 days As 92/510
Accelerated thermal degradation samples 92/642 stored at +20 C, +37 C, +45 C for 570 or 730 days As 92/642
Accelerated thermal degradation samples 92/512 stored at +20 C, +37 C, +45 C for 392 or 552 days As 92/512
preparations have been published (De Boer & Mannaerts 1990 , Hard et al. 1990 , Van Weezenbeek et al. 1990 , Amoresano et al. 1996 , Harris et al. 1996 . The bulk solutions were diluted in an appropriate buffer containing excipients and were distributed into ampoules as 1·0 ml aliquots according to WHO guidelines. Ampoule contents for each preparation are summarised on (Storring et al. 1976 , WHO Expert Committee on Biological Standardization 1989 , 1994 . During the period of this study the stocks of the second ISU were effectively exhausted and the third ISU was established. These two materials appear to be indistinguishable, as previously indicated, and were used interchangeably throughout this study except where they have been directly compared with each other.
Participants and assays contributed to the study
The participants in this study are listed in Table 2 . Throughout this report each laboratory is identified by a number between 1 and 30 which does not relate to the order of listing. (NB Not all numbers have been used.)
In vivo bioassays
Ten laboratories contributed in vivo bioassays based on the gonadotrophin augmentation of ovarian weight gain. These assays are essentially similar and conform to relevant pharmacopoeial monographs: laboratories 25 and 30, European Pharmacopoeia (1986); laboratories 11, 18 and 23, British Pharmacopoeia (1988); laboratories 7, 16, 17, 22 and 29 (Steelman & Pohley 1953) . Each participant was requested to carry out at least two independent assays for each preparation tested preferably using at least three dose levels of each preparation so that linearity and parallelism of dose-response lines could be examined. For the purposes of this study an independent assay was considered to be one in which a freshly made up ampoule of test preparation was tested on a separate occasion using fresh batches of reagents where feasible. Participants were also asked to contribute full results of their assays including all raw data for analysis at NIBSC.
In vitro bioassays and radioreceptor assays
Nine laboratories contributed in vitro bioassays by six methods and three laboratories contributed radioreceptor assays by four methods. Laboratories 9, 10, 26, 28, 29 and 30 used Sertoli cells from immature rats (Guillou et al. 1986 , Padmanabhan et al. 1987 and determined various end points including aromatase activity (laboratory 9), plasminogen activator (laboratory 26) and cAMP production. Four laboratories used human or rat rFSH receptor expressed in various cell types (Tilly et al. 1992 , Gudermann et al. 1994 : laboratory 7, mouse Y1 adrenal cells; laboratory 9, L cells; laboratory 12, human foetal kidney 293 cells; and laboratory 29 CHO cells. End points measured included progesterone and cAMP. Laboratory 8 used aromatase activity in rat granulosa cells (Miro et al. 1991) . For the radioreceptor assays laboratories 9, 10 and 29 used calf testis as a source of FSH receptor (Cheng 1975) and laboratory 29 additionally used human rFSH receptor expressed in CHO cells. Participants were asked to examine preparations using assay designs and contributing results as described for in vivo bioassays.
Immunologically based assays
Nineteen laboratories using 24 assay systems contributed immunologically based assays to the study (Table 3) . Seven laboratories contributed RIA (defined as one-site assays for the purposes of analysis in this study), seven laboratories contributed IRMA and eight laboratories contributed other assay types including ELISA and similar assays with different detection modes including chemiluminescence and fluorescence (defined as two-site assays for the purposes of analysis in this study). The majority of these assays were commercially available assays in kit form which included a kit standard calibrated against the International Reference Preparation for pituitary FSH (Code 78/549). Other assays were in-house assays with standards derived from various sources including the National Institutes for Diabetic, Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA). Participants were asked to carry out at least two independent assays, each to include each of the preparations supplied at as many dilutions as practicable (at least three and preferably six or more) to provide information about the dose-response curves and to return full results of their assays for analysis at NIBSC.
Statistical analysis
In vivo bioassays The majority of participants contributed data for both body weight and organ weight for each response. These data were examined using both organ weight only and organ weight relative to body weight, both as given and following log transformation as the assay response. Within each laboratory the response used for subsequent analysis was that which best satisfied the criteria of statistically valid assays with homogeneous groups of responses and precise estimates of relative potency. Doses with mean responses which contributed significantly to non-linearity and which appeared to be at the extremes of the response range were omitted from analysis. Log potency estimates for the rFSH and purified urinary FSH in terms of the ISU were obtained as the displacement of parallel log dose-(log) response lines from analysis as paired or multiple parallel-line assays. Statistical weights for the paired analysis were computed as the reciprocal of the variance of the log potency. Assays described as statistically valid showed no significant (P>0·05) deviations from linearity or parallelism.
In vitro bioassays, receptor assays and immunoassays
For each assay response data (as far as possible the directly measured values) were plotted against log dose and assessed both graphically and statistically for outliers, consistency of increase (or decrease) of dose-response relationship and homogeneity of variances. Groups of responses with an excessively large variance relative to the variances of other groups in the same assay were examined further. If such groups consisted of only two replicates, both were deleted; individual outlying responses in groups of three or more replicates were deleted. Response-error relationships were examined and where variances showed a significant increase with increasing response, the relationship of variance to mean response raised to a positive power, , was fitted using a maximum likelihood method (Raab 1981) . This relationship, with taken as the average value of for assays of the same type from the same laboratory, was used in subsequent analysis. Dose-response relationships were assessed for conformity to a four parameter logistic function, maximum and minimum responses for each assay were determined using this model, and data for each assay were analysed as parallel-line assays using a logit transformation of the responses (and the program WRANL (Gaines-Das & Tydeman 1982)). Log dose-logit response lines were assessed for linearity and parallelism and log potency estimates were obtained as the displacement of parallel log dose-logit response lines. In a few cases either the response range was so limited that a four parameter logistic model could not be assessed or conformity to this model was not satisfactory and the responses from the linear part of the response range have been analysed as described for in vivo bioassays. Slopes of log dose-logit response lines were examined for any consistent trends. Differences between slopes of coded duplicate preparations were used to provide a direct measure of intra-assay slope variability.
Combination of potency estimates
Estimates of log potency from analysis of in vivo bioassays for specified pairs of preparations were examined for heterogeneity using a chi-squared test and combined as weighted geometric means where estimates were homogeneous, or unweighted geometric means where estimates were heterogeneous. Estimates of log potency from analysis of in vitro bioassays, receptor assays and immunoassays were combined as unweighted geometric means. Fiducial limits for unweighted means were determined from the variance of the logarithms of the combined estimates. Comparisons among groups of estimates were made using unweighted analysis of variance of the log potency estimates of the groups compared. Inclusion, where possible, of a coded duplicate of one of the FSH preparations provided a direct measure of the intra-assay variation of potency estimates calculated as the Figure 1 Individual estimates of FSH content for ampoules of 92/512, expressed as IU of the ISU in ampoules coded 71/223 plotted on a log scale. Each square denotes an individual estimate. The three character code in the square indicates the assay type (B denotes in vivo assay; R receptor assay, I in vitro assay; i two-site immunoassay and r one-site immunoassay) followed by the laboratory number. Shading has been added to emphasise assay type: open squares are in vitro bioassays or receptor assays, solid squares are in vivo assays, hatched squares are one-site assays and dotted squares are two-site assays. Double squares with a single code indicate two estimates which were obtained in the same assay using differently labelled ampoules. The arrowed number shows the weighted geometric mean of the estimates by bioassay.
deviation of the log relative potency estimate of the duplicate in terms of the identical material from its expected value of 0. This is taken to provide a measure of the minimum inherent variability in these systems, and is taken as the base against which comparisons among other estimates are considered.
Results
Comparison of the second and third ISU
Over the period of this study the second ISU (in ampoules coded 71/223) was replaced by the third ISU (in ampoules 71/264). These two preparations were derived from the same bulk material and were ampouled under identical conditions. Several of the laboratories received ampoules of both preparations. Pairwise comparison of these two preparations confirmed the continuity of this unitage. Nine independent in vivo bioassays in six laboratories were statistically valid and gave estimates which were homogeneous with a weighted geometric mean (95% fiducial limits) of 0·99 (0·91-1·08) IU of the second ISU equivalent in activity to 1 IU of the third ISU (data not shown). These two preparations were also compared in 39 assays in 14 immunoassay systems. Slopes of log dose-logit response lines for these two preparations were similar and estimates of the relative potency of 71/264 in terms of 71/223 (IU/IU) ranged from 0·80 to 1·20 with an unweighted geometric mean (95% limits) of 1·02 (0·99 to 1·05) IU/IU. For subsequent analysis these two preparations have been treated as identical and referred to as a single preparation (ISU). Where one (but not both) of the second or the third ISU, was included in an assay, it has been recorded as the ISU. Where both preparations were included in the same assay, responses have been combined and treated as if given by a single preparation so that maximum precision is obtained for calibrations in terms of the ISU.
Dose-response relationships for rFSH, purified urinary FSH and ISU
In vivo bioassays Seven of the ten participants provided data for both body weights and organ weights. In general the response used for analysis was log transformed organ weight relative to body weight. This response was also used for consistency in the few cases where there was no clear advantage of one response transformation, and for the one participant who supplied this response without separate data for body weights. Two participants supplied organ weight responses only; in one case log transformed response, and in the other untransformed response, gave more precise estimates of relative potency. Analysis of pairwise comparisons was statistically valid for the majority of assays with fewer than 5% exceptions.
In vitro bioassays and receptor assays Log dose-logit response lines for the four preparations in these assays did not show consistent significant deviations from linearity or parallelism; except in the receptor assays using CHO cells there was a tendency for 92/642 to give steeper doseresponse lines than the ISU and 92/512 (92/510 was not included in these assays). However, only marked instances of non-parallelism would have been detected for many of these assays because of the limited number of doses tested in a number of assays and because of the variability of the measured responses in many assays.
Immunoassays For 16 of the 24 assay systems in this study log dose-logit response lines did not differ significantly and consistently from linearity or parallelism, although all four preparations were not included in five of those assay systems. In laboratory 24, these four preparations were tested at a single dose and results from this assay system have been excluded from this analysis. In the remaining assay systems there was a tendency for the dose-response lines for the ISU or 92/642, or rarely both, to differ consistently from those of other preparations. Although these data indicate that some differences in sensitivity or selectivity exist between different assay systems, which is to be expected, the magnitude of the differences are not sufficient to preclude use of any preparation as an IS.
Variability of estimates
A measure of the within-assay accuracy and precision of the assays contributed was enabled by inclusion within some in vitro and receptor assays and within most immunoassays of coded duplicates (ampoules of the same material coded with different letters for assay) and by the need to confirm the continuity of unitage between the second and third ISU. It is expected that the relative potency of coded duplicates to one another should be 1, and similarly of the third and second ISU assuming these preparations to be identical. Deviations of the relative potency from the value of 1 reflect variability within the assay. Consistent differences within a laboratory from the value of 1 and consequent differences between laboratories may result if there is a consistent bias in the assay system.
Comparison by in vivo bioassay and by immunoassay of the third ISU with the second ISU gave estimates of relative potency which did not differ significantly from 1 and which showed no greater variability between laboratories and assays than within laboratories and assays. Comparison by immunoassay gave geometric coefficients of variation (gcv) of about 10% both within and between assays and laboratories.
Coded duplicates of one of the rFSH preparations or of the purified urinary FSH were included in most immunoassays and a number of in vitro or receptor assays. For each pair of duplicates and each type of assay, estimates showed within-and between-assay variabilities and betweenlaboratory variabilities which were broadly similar. All estimates for duplicates were therefore used to give pooled variances for each assay type. The gcv for immunoassays was about 10% or less both within and between assays and was similar or marginally larger between laboratories. For in vitro bioassays the within-and between-assay gcvs were each about 50% while laboratory geometric means had a gcv of about 30%. For receptor assays, variances within and between assays and between laboratories were similar, with gcvs generally between 10 and 15%.
Variability between assays within laboratories was examined directly for all comparisons by each type of assay, including in vivo bioassays. For immunoassays the intralaboratory variability was smallest with gcv less than 10% for virtually all comparisons. For receptor assays the intra-laboratory gcv was generally between 10 and 15%. For in vivo bioassays the intra-laboratory gcv, determined directly using unweighted estimates of potency, was generally about 25%. In vitro bioassays gave the largest intra-laboratory variability with gcvs from 40 to 70%.
Calibration of the IS for FSH, human urinary (urofollitropin) in ampoules coded 92/512, the IS for human rFSH in ampoules coded 92/642 and a preparation of rFSH in ampoules coded 92/510 in terms of the ISU
Calibration by in vivo bioassays Laboratory geometric mean estimates are given in Table 4 and individual estimates are shown in Figs 1-3. Comparison of the IS for human urinary FSH (urofollitropin), with the ISU was carried out in 21 independent assays in eight laboratories. After deletion of estimates from two statistically invalid assays and of one estimate which contributed significantly to the heterogeneity chi-squared value, the remaining estimates were broadly similar (P0·03 for chi-squared value for heterogeneity) with an unweighted geometric mean of 126 IU of ISU per ampoule. Deletion of an additional estimate which contributed most to the heterogeneity chi-squared value gave a group of 17 estimates which did not differ significantly from homogeneity and which had a weighted geometric mean (95% fiducial limits) of 121 (113-128) IU of the ISU per ampoule of 92/512.
Comparison of the IS for human rFSH with the ISU was carried out in 26 independent assays in nine laboratories. The weighted geometric mean (95% fiducial limit) of 25 homogeneous estimates (after deletion of one estimate from a statistically invalid assay) was 138 (131-145) IU of the ISU per ampoule of 92/642.
Comparison of the rFSH preparation in ampoules coded 92/510 with the ISU was carried out in 24 independent assays in nine laboratories. All assays were statistically valid, but one estimate contributed significantly to the heterogeneity chi-squared value both within the laboratory in which it was obtained, and over all estimates, and has been deleted. The remaining 23 estimates did not differ significantly from homogeneity and gave a weighted geometric 
Calibration by in vitro bioassays and receptor assays
Laboratory geometric mean estimates are given in Table 5 and individual estimates are shown in Figs 1-3.
Estimates by receptor assays for 92/512, with an unweighted geometric mean of laboratory means (95% limits) of 80 (74 to 86) IU per ampoule, were markedly smaller than those obtained by in vivo bioassay. For both of the rFSH preparations 92/642 and 92/510, estimates by receptor assays were significantly larger than those obtained by in vivo bioassays, namely 167 (150-185) IU per ampoule for 92/642 and 121 (107 to 138) IU per ampoule for 92/510. Estimates by in vitro bioassays varied widely with overall means similar to those obtained by receptor assays. Because of the large intra-laboratory variability, the extent to which the estimates by in vitro bioassay in the different laboratories reflect inter-laboratory differences is not clear. For each calibration, the inter-laboratory variability for estimates by in vitro bioassay tends to be larger than the pooled intra-laboratory variability, with the largest for the calibration of rFSH preparation coded 92/510.
Calibration by immunoassays
Laboratory mean geometric estimates are given in Table 6 For calibration of each of the three ampouled preparations, over all immunoassays or over one-and two-site immunoassays separately, the inter-laboratory variability was larger than the pooled intra-laboratory variability. For two-site immunoassays and for all immunoassays considered together, the inter-laboratory variability for calibration of 92/512 was less than half that for calibration of 92/510 or 92/642. Estimates by one-site assays were less, for each calibration, than estimates by two-site assays with the difference being least for calibration of 92/512. (One-site estimates were 5, 15 and 12% less than estimates from two-site assays for 92/512, 92/642 and 92/510 respectively.)
Comparison of the IS for human rFSH in ampoules coded 92/642 and a preparation of human rFSH in ampoules coded 92/510 with the IS for human urinary FSH (urofollitropin) coded 92/512
Comparisons by in vivo bioassay The IS for human rFSH was compared directly with the IS for FSH, human, urinary in 15 in vivo bioassays (Table 7 and Fig. 4) . One of these estimates contributed significantly to the heterogeneity chi-squared value both within the laboratory in which it was obtained, and over all estimates, and has been deleted. The remaining 14 estimates did not differ significantly from homogeneity and had a weighted geometric mean (95% limits) of 138 (129-148) IU of the IS for FSH, human urinary per ampoule. This value is virtually identical to the value obtained by calibration of the IS for human rFSH in terms of the ISU. The rFSH in ampoules coded 92/510 was compared directly with the IS for human urinary FSH in 16 in vivo bioassays (Table 7 and Fig. 5 ). Three of these assays showed significant deviations from parallelism and were deleted. Further deletion of one estimate, which contributed most greatly to the heterogeneity chi-squared value, gave a group of estimates which did not differ significantly from homogeneity, and which had a weighted geometric mean (95% limits) of 85 (79 to 92) IU of the IS for human urinary FSH per ampoule. This is similar to the value obtained by calibration of this preparation in terms of the ISU, although being based on only half the number of assays, may be less reliable.
Comparisons by in vitro bioassays and receptor assays Estimates obtained by direct comparisons of 92/ 642 and 92/510 with the IS for human urinary FSH are shown in Table 8 and Figs 4 and 5. Overall estimates by both in vitro bioassays and receptor assays are some two times larger than those obtained by in vivo bioassay using the IS for human urinary FSH as standard. These estimates are also larger, by a factor of about 1·5, than estimates obtained by calibration of these preparations by in vitro bioassays or receptor assays in terms of the ISU. The inter-laboratory variability for comparisons by in vitro bioassay of 92/642 with the IS for human urinary FSH is not larger than the intra-laboratory variability. However, comparisons of 92/510 with the IS for human urinary FSH show somewhat less inter-laboratory consistency. There are receptor assays in only two laboratories for the latter comparison. However, comparison of 92/642 with the IS for human urinary FSH gave a larger estimate in receptor assays using CHO cells expressing rFSH receptors than in assays using the classical calf testis membrane assay.
Comparisons by immunoassays
Estimates obtained by direct comparisons of 92/642 and 92/510 with the IS for human urinary FSH are shown in Table 9 and Figs 4 and 5. These estimates are significantly larger than those obtained by immunoassay using the ISU as standard and are also larger than estimates obtained by in vivo bioassay for these comparisons. Excluding laboratories 30 and 8, the inter-laboratory variability for either comparison is slightly more variable than the intra-laboratory variability.
Comparison of a preparation of human rFSH in ampoules coded 92/510 with the IS for human rFSH
Comparisons by in vivo bioassay The rFSH preparation in ampoules coded 92/510 was compared directly with the IS for human rFSH in 22 in vivo bioassays (Table 7 and Fig. 6 ). Two of these assays showed significant deviations from parallelism and were deleted. The remaining 20 estimates did not differ significantly from homogeneity and had a weighted geometric mean (95% limits) of 95 (89-100) IU of the IS for human rFSH per ampoule. This is virtually identical to the value obtained by calibration of this preparation in terms of the ISU and similar to the value obtained by comparison of this preparation with the IS for human urinary FSH.
Comparisons by in vitro bioassays and receptor assays Estimates obtained by direct comparisons of 92/ 510 with the IS for human rFSH are shown in Table 8 and Fig. 6 . Overall estimates by both in vitro bioassays and receptor assays are larger than those obtained by in vivo bioassay using the IS for human rFSH as standard. However, these estimates are similar to estimates obtained by calibration of this preparation by in vitro bioassays or receptor assays in terms of the IS for human urinary FSH. The inter-laboratory variability for this comparison was not significantly larger than the intra-laboratory variability.
Comparisons by immunoassay Estimates obtained by direct comparisons of 92/510 with the IS for human rFSH are shown in Table 9 and Fig. 6 . These estimates are about 10% smaller than those obtained by in vivo bioassay using the IS for human rFSH as standard, and about 30% larger than those obtained by immunoassay using the IS for human urinary FSH as standard. With the previously noted exclusions, the inter-laboratory variability for the comparison by immunoassay of 92/510 and the IS for human rFSH was only marginally more variable than the inter-laboratory variability and similar to that obtained for the comparisons of the IS for human rFSH and the IS for human urinary FSH.
Accelerated thermal degradation studies of the candidate standards
Samples of each of the ampouled purified preparations of FSH which had been stored at elevated temperatures for 1-2 years (ATD samples) were compared within the same assay with ampoules of the same preparation which had been stored continuously at 20 C. The ATD samples of 92/642 did not differ significantly from the samples stored at 20 C in two in vivo bioassays. Estimates of the activity of ATD samples of both 92/510 and 92/512 relative to samples stored continuously at 20 C in two to four bioassays showed a loss of about 30% for samples stored at 45 C and a loss of 10-15% for samples stored at 20 C. Based on these results and using an Arrhenius equation for prediction, predicted yearly losses of activity at 20 C for either of these two preparations would be less than 0·1%.
For each of the three ampouled preparations, estimates by in vitro bioassays for the ATD samples and the samples stored continuously at 20 C did not differ significantly from one another relative to the intra-assay and intra-laboratory variability.
Estimates by immunoassays and receptor assays for ATD samples of each of the three ampouled preparations differed significantly between different assay systems, although estimated losses of activity were generally less than those obtained by in vivo bioassays except for 92/642, and not detectable by some assay systems. This indicates that these various assay systems show significantly different specificities for the degraded and less biologically active FSH.
On the basis of these results, each of the ampouled preparations appears to be sufficiently stable to serve as a standard.
Discussion
Separate standards for FSH from pituitaries and from post-menopausal urine were established in the 1960s on the basis that gonadotrophins extracted from these two sources differed from one another, although the unitages for each were derived from a common preparation. The ISU is the standard in current use for calibration by bioassay of therapeutic products. However, the development and therapeutic use of high purity and rDNA-derived preparations of FSH has led to a review of standards for therapeutic FSH preparations. This study has provided comparisons of the ISU with candidate preparations of high purity urinary FSH and of rFSH.
Calibration of candidate IS by in vivo bioassay
Some 25 comparisons by in vivo bioassay for each of the candidate preparations with the ISU gave assays which were broadly statistically valid and estimates of relative potency which, for each comparison, were homogeneous, with a maximum of two heterogeneous estimates for any comparison. Thus, for each candidate standard, valid calibration by in vivo bioassay in terms of the ISU was obtained, giving for 92/512 a weighted geometric mean (95% fiducial limits) of 121 (113-128) IU per ampoule, for 92/642 a weighted geometric mean of 138 (131-145) IU per ampoule, and for 92/510 a weighted geometric mean of 95 (90-100) IU per ampoule.
These results are consistent with studies which have found that the in vivo biological activity of rFSH (De Boer & Mannaerts 1990 , Galway et al. 1990 , and its pharmacokinetic and pharmacodynamic characteristics (Porchet & le Cotonnec 1994 , Weinbauer et al. 1994 ) are similar to those of urinary FSH, and that rFSH gave a doseresponse curve in the Steelman-Pohley bioassay which was parallel to a menotrophin standard and linear in the same part of the curve. Thus clinical protocols and dosage regimens similar to those for urinary FSH have been proposed for rFSH (Porchet & le Cotonnec 1994) .
Since rFSH preparations appear to behave overall in a manner similar to preparations derived from urinary sources and in the interests of maintaining continuity of unitage from one standard to another and hence from one therapeutic product to another the IS for rFSH was calibrated directly in terms of the IS for menotrophin.
Comparisons by in vitro bioassay
In the present study estimates of activity by in vitro bioassays showed significant differences between laboratories. The variability of estimates obtained from in vitro bioassays may reflect the selectivity or specificity of these assays which in general select only one action of FSH as a measurable end point. A number of studies have compared in vitro bioactivity, or structural features of rFSH with preparations derived from natural sources. Thus rFSH has been found to have similar activity to natural FSH in some in vitro assay systems (Galway et al. 1990 , Mannaerts et al. 1991 , Mason et al. 1993 and to be more potent in other assay systems , Lambert et al. 1995 . Results obtained here using receptor binding assays were more consistent between laboratories than those from in vitro bioassays but there were a limited number of systems used. However, it may be that receptor binding and signal transduction are dissociable functions which require separate sites of the FSH molecule (Valove et al. 1994) . Thus while receptor binding may require properties of FSH which are consistent between different preparations, in vitro bioassays may determine properties which are variable between different preparations. 
